Industry News prev next
Sep 26 2006
Alcon's Travatan Z Solution Receives FDA Approval
On September 21, 2006, Alcon, Inc. announced that that the U.S. Food and Drug Administration (FDA) has approved TRAVATAN Z (travoprost ophthalmic solution) 0.004% for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension, who are intolerant of or insufficiently responsive to other intraocular pressure lowering medications.
TRAVATAN Z is a new formulation that eliminates benzalkonium chloride (BAK) from Alcon’s existing TRAVATAN solution and replaces BAK with sofziatim, a robust ionic buffered preservative system that is gentle to the ocular surface. Alcon developed this BAK-free version of TRAVATAN because long-term use of topical solutions containing BAK may compromise the ocular surface and exacerbate conditions such as dry eye.
To read the full press release about TRAVATAN Z, click below.
